<code id='ADED80DEFA'></code><style id='ADED80DEFA'></style>
    • <acronym id='ADED80DEFA'></acronym>
      <center id='ADED80DEFA'><center id='ADED80DEFA'><tfoot id='ADED80DEFA'></tfoot></center><abbr id='ADED80DEFA'><dir id='ADED80DEFA'><tfoot id='ADED80DEFA'></tfoot><noframes id='ADED80DEFA'>

    • <optgroup id='ADED80DEFA'><strike id='ADED80DEFA'><sup id='ADED80DEFA'></sup></strike><code id='ADED80DEFA'></code></optgroup>
        1. <b id='ADED80DEFA'><label id='ADED80DEFA'><select id='ADED80DEFA'><dt id='ADED80DEFA'><span id='ADED80DEFA'></span></dt></select></label></b><u id='ADED80DEFA'></u>
          <i id='ADED80DEFA'><strike id='ADED80DEFA'><tt id='ADED80DEFA'><pre id='ADED80DEFA'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion